


Pharmaceuticals & Biotechnology | Small Cap
Infinium Pharmachem Ltd demonstrates a mixed financial performance. The company excels in solvency and profitability, indicating a strong ability to meet long-term obligations and generate profits. Growth prospects are also promising, driven by robust revenue and asset expansion. However, liquidity faces challenges due to negative operating cash flow, and efficiency is hampered by inventory and capital turnover issues. Financial metrics like earnings per share and book value per share raise concerns. While coverage of interest expenses is adequate, the absence of dividend coverage is notable. The company's strengths in profitability and solvency are partially offset by weaknesses in liquidity and efficiency, requiring attention to optimize working capital and improve operational performance. Overall, the company exhibits a blend of financial strengths and areas needing improvement for sustained growth and stability.
Infinium Pharmachem Ltd demonstrates a mixed financial performance. The company excels in solvency and profitability, indicating a strong ability to meet long-term obligations and generate profits. Growth prospects are also promising, driven by robust revenue and asset expansion. However, liquidity faces challenges due to negative operating cash flow, and efficiency is hampered by inventory and capital turnover issues. Financial metrics like earnings per share and book value per share raise concerns. While coverage of interest expenses is adequate, the absence of dividend coverage is notable. The company's strengths in profitability and solvency are partially offset by weaknesses in liquidity and efficiency, requiring attention to optimize working capital and improve operational performance. Overall, the company exhibits a blend of financial strengths and areas needing improvement for sustained growth and stability.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
32.65
Industry Median
30.92
Small Cap Median
28.82
P/E RATIO
26.92
P/B RATIO
2.70
Industry Median
3.39
Small Cap Median
2.92
P/S RATIO
1.90
Industry Median
3.36
Small Cap Median
2.72
Others
PEG RATIO
0.75
EV/EBITDA RATIO
13.81
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹209.95 as on Aug 6, 2026.
The growth ratios reveal a strong expansion in revenue and assets, but challenges in earnings per share and net income growth. The robust revenue growth rate and asset growth rate indicate successful market penetration and investment in new opportunities. However, the decline in earnings per share and net income growth needs attention to ensure profitability keeps pace with revenue. While the company is expanding, sustainable profitability must be a key focus.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 39.44 | 15.15 | 19.3 | 14.71 | 21.79 |
| Operating Profit Growth Rate | 100 | 60 | 18.75 | 0 | 15.79 |
| Earnings Per Share (EPS) Growth | 124.63 | -69.56 | -12.69 | -35.59 | 49.14 |
| Asset Growth Rate | 73.53 | 20.34 | 19.72 | 132.94 | -11.62 |
| Net Income Growth Rate | 133.33 | 42.86 | 20 | -33.33 | 75 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Kilitch Drugs (India) Ltd | 7.12 | 22.83 | Neutral | 37.00 | 9.27 | 30.00 |
| 2 | Medico Remedies Ltd | 6.61 | 37.70 | Overvalued | 17.00 | 1.58 | 13.00 |
| 3 | SMS Lifesciences India Ltd | 6.59 | 21.63 | Undervalued | 45.00 | 58.80 | 19.00 |
| 4 | Infinium Pharmachem Ltd | 6.42 | 26.92 | Neutral | 22.00 | 6.43 | 14.00 |
| 5 | Medicamen Biotech Ltd | 5.73 | 33.43 | Neutral | 20.00 | 6.94 | 10.00 |
| 6 | Aarey Drugs & Pharmaceuticals Ltd | 5.73 | 58.43 | Neutral | 7.00 | 1.40 | 4.00 |
| 7 | Albert David Ltd | 5.63 | -279.90 | Neutral | 5.00 | -2.62 | -1.00 |
| 8 | BPL Ltd | 5.46 | -30.53 | Neutral | -4.82 | -1.69 | -8.55 |
| 9 | Zim Laboratories Ltd | 5.41 | 41.96 | Neutral | 30.00 | 1.11 | 6.00 |
| 10 | Lyka Labs Ltd | 4.77 | -26.63 | Neutral | -4.00 | -8.93 | -10.00 |
| 11 | Nectar Lifescience Ltd | 3.83 | -2.67 | Neutral | -59.00 | -2.95 | -293.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish